arginyl-glycyl-aspartyl-serine has been researched along with fura-2 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heemskerk, JW; Hoyland, J; Mason, WT; Sage, SO | 1 |
| Doi, H; Ikeo, T; Karasawa, T; Katoh, M; Narita, H; Odawara, A; Takagi, M | 1 |
| Lages, B; Weiss, HJ | 1 |
3 other study(ies) available for arginyl-glycyl-aspartyl-serine and fura-2
| Article | Year |
|---|---|
Spiking in cytosolic calcium concentration in single fibrinogen-bound fura-2-loaded human platelets.
Topics: Adenosine Diphosphate; Blood Platelets; Calcium; Cytosol; Egtazic Acid; Fibrinogen; Fura-2; Humans; Kinetics; Oligopeptides; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Signal Transduction; Time Factors | 1992 |
Antiplatelet mechanisms of TA-993 and its metabolite MB3 in ADP-induced platelet aggregation.
Topics: Actins; Adenosine Diphosphate; Blood Platelets; Calcium; Cyclic AMP; Cyclic GMP; Diltiazem; Dose-Response Relationship, Drug; Fibrinogen; Fura-2; Humans; Male; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Binding | 2000 |
Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Calcium; Cytosol; Enzyme Inhibitors; Eptifibatide; Fura-2; Humans; Immunoglobulin Fab Fragments; Immunoglobulin Fragments; Oligopeptides; Peptides; Peptides, Cyclic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thiazolidines; Thromboplastin | 2001 |